PL3302549T3 - Terapia skojarzona z zastosowaniem przeciwciała anty-CD20 z inhibitorem Bcl-2 i inhibitorem MDM2 - Google Patents

Terapia skojarzona z zastosowaniem przeciwciała anty-CD20 z inhibitorem Bcl-2 i inhibitorem MDM2

Info

Publication number
PL3302549T3
PL3302549T3 PL16725104T PL16725104T PL3302549T3 PL 3302549 T3 PL3302549 T3 PL 3302549T3 PL 16725104 T PL16725104 T PL 16725104T PL 16725104 T PL16725104 T PL 16725104T PL 3302549 T3 PL3302549 T3 PL 3302549T3
Authority
PL
Poland
Prior art keywords
inhibitor
bcl
antibody
combination therapy
mdm2
Prior art date
Application number
PL16725104T
Other languages
English (en)
Inventor
Christian Klein
Frank Herting
Markus Dangl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL3302549T3 publication Critical patent/PL3302549T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16725104T 2015-05-26 2016-05-23 Terapia skojarzona z zastosowaniem przeciwciała anty-CD20 z inhibitorem Bcl-2 i inhibitorem MDM2 PL3302549T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15169199 2015-05-26
EP16725104.0A EP3302549B1 (en) 2015-05-26 2016-05-23 Combination therapy of an anti cd20 antibody with a bcl-2 inhibitor and a mdm2 inhibitor
PCT/EP2016/061517 WO2016188935A1 (en) 2015-05-26 2016-05-23 Combination therapy of an anti cd20 antibody with a bcl-2 inhibitor and a mdm2 inhibitor

Publications (1)

Publication Number Publication Date
PL3302549T3 true PL3302549T3 (pl) 2019-11-29

Family

ID=53264535

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16725104T PL3302549T3 (pl) 2015-05-26 2016-05-23 Terapia skojarzona z zastosowaniem przeciwciała anty-CD20 z inhibitorem Bcl-2 i inhibitorem MDM2

Country Status (31)

Country Link
US (1) US20160347852A1 (pl)
EP (1) EP3302549B1 (pl)
JP (1) JP6612362B2 (pl)
KR (1) KR102043803B1 (pl)
CN (1) CN107847600B (pl)
AR (1) AR104735A1 (pl)
AU (1) AU2016267564B2 (pl)
BR (1) BR112017023517A2 (pl)
CA (1) CA2984706A1 (pl)
CL (1) CL2017002983A1 (pl)
CR (1) CR20170529A (pl)
DK (1) DK3302549T3 (pl)
ES (1) ES2744624T3 (pl)
HK (1) HK1252855A1 (pl)
HR (1) HRP20191585T1 (pl)
HU (1) HUE044853T2 (pl)
IL (1) IL255353B (pl)
LT (1) LT3302549T (pl)
MA (1) MA44645B1 (pl)
MX (1) MX2017014977A (pl)
MY (1) MY188849A (pl)
NZ (1) NZ736727A (pl)
PE (1) PE20180454A1 (pl)
PL (1) PL3302549T3 (pl)
PT (1) PT3302549T (pl)
RS (1) RS59204B1 (pl)
RU (1) RU2727196C2 (pl)
SI (1) SI3302549T1 (pl)
UA (1) UA124617C2 (pl)
WO (1) WO2016188935A1 (pl)
ZA (1) ZA201707357B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9539251B2 (en) 2012-09-07 2017-01-10 Genentech, Inc. Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CN111372613A (zh) * 2017-11-22 2020-07-03 诺帝克纳诺维科特公司 放射免疫缀合物与其他药物联合治疗非霍奇金淋巴瘤
KR20200108302A (ko) 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
KR20200139139A (ko) * 2018-07-31 2020-12-11 어센테지 파마 (쑤저우) 컴퍼니 리미티드 리툭시맙 및/또는 벤다무스틴과 병용된 Bcl-2 억제제 또는 CHOP와 병용된 Bcl-2 억제제의 시너지적 항종양 효과
TWI725488B (zh) 2018-07-31 2021-04-21 大陸商蘇州亞盛藥業有限公司 Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途
EP3883634A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
JP2014507384A (ja) * 2010-12-16 2014-03-27 ロシュ グリクアート アーゲー Ｍｄｍ２阻害剤とのアフコシル化ｃｄ２０抗体の併用療法

Also Published As

Publication number Publication date
ZA201707357B (en) 2020-05-27
SI3302549T1 (sl) 2019-10-30
HRP20191585T1 (hr) 2019-11-29
CA2984706A1 (en) 2016-12-01
JP2018515583A (ja) 2018-06-14
IL255353B (en) 2021-08-31
CR20170529A (es) 2018-01-26
AR104735A1 (es) 2017-08-09
KR102043803B1 (ko) 2019-11-12
AU2016267564B2 (en) 2022-09-01
DK3302549T3 (da) 2019-09-16
RU2017145649A3 (pl) 2019-10-23
WO2016188935A1 (en) 2016-12-01
NZ736727A (en) 2022-09-30
US20160347852A1 (en) 2016-12-01
RS59204B1 (sr) 2019-10-31
MA44645B1 (fr) 2019-09-30
EP3302549B1 (en) 2019-07-03
MX2017014977A (es) 2018-03-23
HK1252855A1 (zh) 2019-06-06
PT3302549T (pt) 2019-09-09
RU2017145649A (ru) 2019-06-26
KR20180004285A (ko) 2018-01-10
LT3302549T (lt) 2019-09-25
CN107847600A (zh) 2018-03-27
HUE044853T2 (hu) 2019-11-28
EP3302549A1 (en) 2018-04-11
UA124617C2 (uk) 2021-10-20
MY188849A (en) 2022-01-09
JP6612362B2 (ja) 2019-11-27
AU2016267564A1 (en) 2017-11-16
CN107847600B (zh) 2021-09-03
BR112017023517A2 (pt) 2018-07-24
IL255353A0 (en) 2017-12-31
CL2017002983A1 (es) 2018-05-04
ES2744624T3 (es) 2020-02-25
PE20180454A1 (es) 2018-03-05
RU2727196C2 (ru) 2020-07-21

Similar Documents

Publication Publication Date Title
IL255353A0 (en) Combined treatment of anti-cd20 antibody with bcl-2 inhibitor and mdm2 inhibitor
HK1222803A1 (zh) 抗體與 抑制劑的組合療法
IL259713A (en) Anti-dr5 antibodies and methods of using them
IL248540A0 (en) A combination of an antibody against ccr4 and an agonist of 4-1bb for the treatment of cancer
IL250566A0 (en) Anti-lag3 antibodies and antigen-binding fragments
IL265274A (en) Combined treatment of antibody and checkpoint inhibitor
HK1255916A1 (zh) 組織蛋白去乙醯酶抑制劑與免疫檢查點抑制抗體的合併癌症治療
HK1250142A1 (zh) 以組織蛋白去乙醯酶抑制劑及反細胞程式死亡受體-1 抗體的組合治療癌症
PT3445785T (pt) Anticorpos anti clever-1 humanizados e sua utilização
IL259416A (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer
ZA201903302B (en) Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
TH1601002552A (th) การบำบัดแบบการรวมของ แอนทิบอดีแอนทิ cd20 กับสารยับยั้ง btk